News for hackers. Stuff that matters.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by rayiner on Wednesday May 24, 2017 @06:08PM (#14413862)
This article does a pretty good job of grappling with the fact that you can't have your cake and eat it too. On one hand the article acknowledges that treatments for orphan diseases have been successful, and many more have come out since the Orphan Drug Act was passed, as compared to before when these diseases were largely ignored. At the same time, it notes that clearly this is a lot of money to spend on one patient.

There is a tendency to believe that the normal dynamics of markets should be suspended when the product is "really important." Of course, that's backward. When the product is really important, the worst thing you can do is turn it into a low-profit economic ghetto by reducing incentives to invest. At the same time, when the government takes over the role of the market by granting a temporary monopoly, there clearly has to be some backstop at work.

The interesting thing to note that the company in the article, Alexion, is not even an unusually lucrative company. In 2015 its operating income was $536 million on 2.6 billion of revenue, or about a 20% operating profit margin. For comparison, Alphabet's operating margin is over 25%. Google also does much better in terms of return on equity and revenue per employee metrics.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by frgtpsswrdlame on Wednesday May 24, 2017 @07:57PM (#14414362)
>The interesting thing to note that the company in the article, Alexion, is not even an unusually lucrative company. In 2015 its operating income was $536 million on 2.6 billion of revenue, or about a 20% operating profit margin.

...what. 20% margin isn't good nowadays? And why on earth are we comparing this company to a tech giant, they're not in the same world when it comes to how they operate. Of course google's going to look better in a lot of these terms, it's google (and i'd argue a monopoly). I mean at what point do we say, actually these biotech companies are plenty profitable? There's so much handwringing about how if we hurt these companies in anyway then all these sick people will die. It's just not true. Why don't we take the S&P 500, a Biotech Index and ALXN and put them on a chart:

https://www.google.com/finance?chdnp=1&chdd=1&chds=1&chdv=1&...

Well damn, looks like despite all their huge R&D costs, only 20% margins, so on and so on they are doing pretty damn well. Honestly, are we looking at the same chart? These companies are MILKING sick people and we're afraid to intervene. Markets don't work in life and death scenarios because people would pay anything. This is a case that begs for regulation and even with it these companies are going to be just fine.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by tuna-piano on Wednesday May 24, 2017 @08:14PM (#14414447)
In a world where investors invest in photo sharing apps and social media websites because of the potential billion dollar payouts - why would you limit the potential drug payouts without limiting the social media app payouts?

Over time, would limiting the potential profits in life-saving drugs increase or decrease the number of life-saving drugs developed?

In an economy where people can choose to work in any field, and investors can choose to invest their money in any field - what better way is there to allocate the people and money resources than by letting people voice how valuable something is with their wallets? Do you want to force someone to buy a third car instead of buying a new drug treatment?

If you understand the invisible hand theory (actually understand it, not just the everyman's definition) I think it's difficult to (a) argue against in general and (b) argue against for certain life-saving industries especially.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by frgtpsswrdlame on Wednesday May 24, 2017 @08:26PM (#14414502)
Actually, horror of horrors, if I could I'd take a giant antitrust bat to about half the technology sector (which would hurt profits).

I urge urge urge you to reevaluate your understanding of economics as well. I recently made a book recommendation on here, I'd like to make it again.

23 Things They Don't Tell You About Capitalism by Ha-Joon Chang

Economism by James Kwak

And no it's not at all hard to argue against the invisible hand theory although I'd really like to not do that here. But just consider how far physics has advanced since the 18th century, why don't you think economics has done the same? Just think about what you're actually proposing for a second. There are no scenarios where the invisible hand works against laypeople? I think that's incredibly naive.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by kevinnk on Wednesday May 24, 2017 @10:54PM (#14415006)
I've recommended to plenty of people that they read "Principles of Macroeconomics" by Greg Mankiw, but weirdly enough no one has. Maybe I just didn't urge urge urge them enough?

Actually, if you believe economics hasn't changed since the 18th century you really should read it. Who knows, maybe you'll even reevaluate your understanding of economics.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by frgtpsswrdlame on Wednesday May 24, 2017 @11:49PM (#14415190)
Principles is the exact wrong thing for someone casually interested in economics to read. It's the proliferation of the belief that Econ 101 is "real econ" when it's anything but. You can get an undergrad degree in Econ and still have no real understanding of how the economy works. Sure you'll have a simple model but that model will fail over and over again because it's far too simplified. That's why I recommend Economism. It's inoculation to Econ 101.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by kevinnk on Thursday May 25, 2017 @04:25AM (#14416025)
I don't really care if people understand "real econ" (whatever that means) but most people haven't even progressed past a folk understanding of economics. Having at least a cursory understanding of why, e.g., price controls lead to scarcity is really a requirement to create an informed criticism of any part of Econ 101. To get to that point, reading through an intro level textbook is exactly what is needed.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by frgtpsswrdlame on Thursday May 25, 2017 @08:14AM (#14416812)
I just don't buy that. Despite being less popular in academia there is absolutely an abundance of politically motivated libertarian/austrian/chicago school blogs, videos and books out there. Many intelligent young people fall down this rabbit hole early and never try to get out. Econ 101 books are only going to solidify their belief that they know economics. Something that challenges the simplified view of economics, that asks when the assumptions of some of these models ever actually apply, about what happens when you start dropping assumptions, about frictions and so on is what's needed. I looked around a bit to find the best article I could from my perspective, maybe you could read it and tell me what you think?

https://www.bloomberg.com/view/articles/2015-11-24/most-of-w...

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by kevinnk on Thursday May 25, 2017 @05:07PM (#14420149)
Any libertarian who takes Econ 101 will find their beliefs challenged tremendously, and not just by the "simple models" you're talking about. To be perfectly blunt, it sounds like you're trying to criticize something that you have an preconceived notion of, but no direct experience with, which is exactly why I was recommending you read Mankiw in the first place. I think you'll be surprised with the amount of time he spends on things like case studies of market failures or why the federal reserve system is a good idea.

As to your link, Noah (whom I respect tremendously) does make a good point, but I think he overstates his case; true, simple supply-demand models don't work in every case (and the minimum wage is a good example of that, although I would counter that most of the non econ101 parts are somewhat short term and restricted to small increases) but for the vast, vast majority of cases people encounter in real life they work surprisingly well. Additionally, supply and demand is only a part of econ 101: Why can't I get tickets to Hamilton without paying a lot? Why do some restaurants charge more for dinner? If we put a tariff on Mexico, who pays? What are the pros and cons of free trade? What does deadweight loss mean? What does the federal reserve do and how does it affect me? What's the relationship between the money supply and inflation? What are the arguments for targeting non zero inflation? Why did we leave the gold standard? Is government debt bad? How is GDP measured? Why does the exchange rate change? Why doesn't the employment rate go to zero? What does the employment rate even mean? How do taxes affect the economy? Do different taxes have different effects? What are the arguments for and against using tax policy to encourage saving? What options does the government have to fight a recession? My city wants to reduce driving downtown, what are some possible policies? What economic policies can we use to fight global warming? What are the arguments for and against rent control? What is a monopoly? All of these questions are easily answered with macroecon 101 level knowledge and most are hard to answer without (we haven't even started talking about micro!) That doesn't mean econ 101 is always applicable, but it does mean you'll have a far better understanding of the world after taking it, even if you do come in with some preconceived notions.

I will say that Noah's suggestion that econ 101 should be more emperical is a good idea, and I especially believe that there should be a stronger emphasis on stats. I actually think that's true of all the social sciences though, and its a separate issue from what you're talking about.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by frgtpsswrdlame on Thursday May 25, 2017 @07:00PM (#14420782)
>To be perfectly blunt, it sounds like you're trying to criticize something that you have an preconceived notion of, but no direct experience with, which is exactly why I was recommending you read Mankiw in the first place.

I don't believe it counts for much but I do have an B.S. in Econ which is to say I have crawled through Macro 101 books and 102 and 200 and so on so I'm aware of what's in Mankiw's book. I would also say that I have no idea of your economics education and I'm not trying to measure dicks here. You may well know more than me, my argument is purely about how to get laypeople to better understand a field I love.

>All of these questions are easily answered with macroecon 101 level knowledge

No! Absolutely not.

>Is government debt bad? ... How do taxes affect the economy? Do different taxes have different effects? What are the arguments for and against using tax policy to encourage saving?

Specifically these questions, the ones in your list that are most likely to come up in casual political conversation are not answered by Econ 101. And other incredibly common political topics like antitrust, minimum wage, other tax questions, wage gaps, welfare, international trade will get no meaningful answer from 101.

Economics is the one field of study in America today where someone who reads three blog posts thinks they're an expert, someone who reads one book, and so on and so on (NOTE: I am also not claiming at all to be an expert. I actually believe that undergrad econ is, unfortunately, a waste of time). My point in encouraging my books (I'm not sure I have the correct language for the point I'm trying to make here so forgive me) is not to make a positive correction and "get people to actually understand economics now" because it's not that simple and frankly 99.9% of people will never understand it because they'll never put in the time to. My books are to encourage a negative correction where people are willing to say "I don't understand economics" just like they'll admit they don't understand programming or physics or psychiatry or anything else. Because there's a lot of people that don't know dick about econ and they're unwilling to admit it. People need to be exposed to complex market failure after complex market failure after complex market failure so they understand the simplified understanding they gained in Business Economics or mises.org is not the real world. Noah doesn't overstate his case he states it exactly right (and much better than I have here).

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by kevinnk on Thursday May 25, 2017 @08:44PM (#14421279)
To reiterate: Most people's thinking on the minimum wage hasn't progressed past "if poor people got paid more they'd be better off, therefore raise the minimum wage." Many people's thinking on walfare haven't evolved past "I don't want to give money to lazy poor people". Sure, someone who's taken Econ101 may not have the ultimately nuanced opinion, but at least their understanding is going to be far closer to reality than someone who hasn't. The ideas in 101 are simplified, but the truth is that they're almost certainly better than whatever was in the person's head before, even if they aren't a complete description.

That being said, if you haven't read Mankiw you really should. He goes into far more detail than you seem to think, on many of the exact subjects you listed. Maybe econ101 has progressed since you last took it.

> Economics is the one field of study in America today where someone who reads three blog posts thinks they're an expert

Ha. It's funny how many fields think this way. A friend of mine who's an MD in sports medicine says the same thing ("People read one exercise book and think they know everything!"). Another friend of mine says the same thing about law. Another says the same about foreign policy. Etc, etc, etc.

If your goal is to get people to people to stop pretending like they know econ after reading one pop-economics​ book, well I don't know what to tell you except that in all likelihood human nature isn't going to change; people have been overconfident about things they don't know "dick" about since the beginning of human history and probably will continue to do so regardless of whether they read your books or not.

By the way, if you really believe that exposure to "complex market failure after complex market failure" is really the answer, there's plenty of places on the internet that do just that. Go to /r/latestagecapitalism or /r/socialism and observe all the nuance and humility that results. In reality, people just as readily end up overconfident in the opposite direction.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by stupidhn on Thursday May 25, 2017 @07:49AM (#14416718)
>but most people haven't even progressed past a folk understanding of economics

There are a few subjects where the average HN denizen thinks they know more than the professionals by having read a mainstream book or two. Economics is one. You can identify these people when they ask, 'How come economists couldn't predict the crisis?'

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by TheOtherHobbes on Thursday May 25, 2017 @06:54AM (#14416502)
Of course absence of price control mechanisms can also lead to scarcity through bubble mechanisms - which can be tamed through taxes.

Ask anyone trying to buy a house in Vancouver.

Does Mankiw mention this in his "requirement for informed criticism"?

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by stupidhn on Thursday May 25, 2017 @07:46AM (#14416704)
>Does Mankiw mention this in his "requirement for informed criticism"?

Are you honestly asking whether Mankiw discusses supply/demand price effects in his textbook?

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by kevinnk on Thursday May 25, 2017 @05:14PM (#14420193)
Prices are high because demand is high and supply is low. Yes, that gets covered.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by cgmg on Thursday May 25, 2017 @01:48AM (#14415508)
Please enlighten us as to how your non-mainstream model is superior. The burden of proof is on you.

Also, your claim that economics hasn't advanced since the 18th century is absurd and betrays an ignorance of the subject.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by frgtpsswrdlame on Thursday May 25, 2017 @07:59AM (#14416758)
>Also, your claim that economics hasn't advanced since the 18th century is absurd and betrays an ignorance of the subject.

Perhaps it was worded poorly but if you reread you can actually see that's the opposite of what I said.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by mrout on Thursday May 25, 2017 @05:46AM (#14416257)
ECON101 isn't 'mainstream economics'. It's incredibly simplified economics.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by barrkel on Thursday May 25, 2017 @05:35AM (#14416220)
Mankiw is a bit of a right wing nutjob, though orthodox in the Chicago school. I wouldn't recommend his books, despite their prevalence in academia.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by stupidhn on Thursday May 25, 2017 @07:44AM (#14416695)
>if I could I'd take a giant antitrust bat to about half the technology sector (which would hurt profits).

That'd be nice on an island. Otherwise, have fun competing against technology behemoths from other nations, some receiving subsidization from the government.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by rokhayakebe on Wednesday May 24, 2017 @11:16PM (#14415076)
You know you are correct. When a photo sharing app sells for billions everyone interviews the founders and praises them. When you save 10 lives and charge billions you are a criminal. I am not sure which one is right or wrong, but it certainly isn't fair to the drug makers.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by tuna-piano on Wednesday May 24, 2017 @11:51PM (#14415202)
You summarize my feelings exactly, in a very clear way that demonstrates the absurdity of the situation.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by dasil003 on Thursday May 25, 2017 @01:24AM (#14415448)
In a vacuum it appears absurd, but to understand why people feel this way, you have to look at the big picture of health care costs spiraling out of control and people literally having to choose between food or meds. Middle class people without health insurance and good retirement savings can end up in poverty because of an unexpected illness. Any attempt at health insurance reform gets twisted and maimed into baseless political showboating—I know several people who voted for Trump because they actually believe he can lower their health insurance bills, the fools.

When people think of a photo sharing app they are thinking of breezy fun social media times. When people think of rare disease treatments the sentiment is much darker a priori. I'm not saying drug companies are to blame for the current situation (hate the game not the player), but emotionally it's obvious why there is judgement about profiting from that situation.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by rayiner on Thursday May 25, 2017 @02:41AM (#14415692)
The problem with the typical person's view of this issue is that it confuses two very different things: price and affordability. Drugs should be priced at a level such that pricing them higher doesn't create enough additional benefit from new drugs to outweigh the extra cost, and pricing them lower causes loss in the benefit from new drugs to outweigh the savings from lower price. That should be decided at a society-wide level.

Affordability is then about transferring money from rich people to poor people so they can buy the appropriately-priced drug.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by TheOtherHobbes on Thursday May 25, 2017 @06:57AM (#14416516)
Well - technically affordability would be more about not transferring money from poor people to rich people without an exceptionally good reason.

A common problem with these arguments is the assumption that they take something from the rich. The reality is the cycle started earlier, and redistribution is a necessary correction to that, not an outrageous and immoral imposition on a presumed natural order.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by rayiner on Thursday May 25, 2017 @07:54AM (#14416739)
There is no economic system in which the skilled educated labor necessary to create these drugs can be compensated by what money you can get from a relatively small number of poor people with s rare disease. You cut $300,000 per year for treatment to $30,000 per year, and this company is operating at huge losses. And it's still not affordable to even normal people.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by thwarted on Thursday May 25, 2017 @09:26PM (#14421474)
When a photo sharing app sells for billions everyone interviews the founders and praises them.

In most of these cases, they've sold something for billions to a single entity that has the money and doesn't strictly need it (for example, if Youtube had not sold to Google it would have been an existential crisis for Youtube, not for Google).

When you save 10 lives and charge billions you are a criminal.

In these ten sales, you've made billions by charging each of the individuals 1/10th of the billions, individuals who don't have the money and do strictly need it.

There's a difference between "sells for billions" and "charges billions": in the former in the case of photo sharing apps, it's a buyer's market, and in the later it's a seller's market.

The founders, the sellers, might get praised in the event of a billion dollar photo sharing app sale, but few have sympathy for the purchasing party in that transaction, no matter what they paid, because it's a buyer's market.

I'm not sure fair, to the drug makers or otherwise, enters into it. These are not really that comparable, and only appear to be due to the scale of the sales both being "billions".

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by tuna-piano on Wednesday May 24, 2017 @08:33PM (#14414530)
I think where we probably agree is that the patent system (which is of course what grants the monopoly pricing power) needs reformation.

I think where we disagree is that I don't think I (or anyone else) knows how much resources society should spend on drug treatments. I strongly believe that the best way to determine how much money society should spend on drug treatments is just to let all the individuals decide how much they should spend on drug treatments (or insurance which covers drug treatments). (This is not saying, however, that you can't have transfer programs which transfer wealth from rich->poor)

In the end, the failures of central planned economies are the same as the failures of central planned sectors, including healthcare.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by emodendroket on Wednesday May 24, 2017 @11:13PM (#14415067)
If your choices are to take a drug or die obviously you will do whatever you can to pay, but that hardly means the price is reasonable.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by foota on Wednesday May 24, 2017 @08:56PM (#14414626)
I think here's the issue, an individual can only decide to spend on a life saving drug treatment if it exists.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by lacker on Thursday May 25, 2017 @02:19AM (#14415620)
It's not that 20% isn't good. It's that, this drug costs $389,000 a year and they are only making 20% margins. So, even if they were a nonprofit they would still have to be charging $311,000 a year to break even. You can argue they shouldn't be profitable, and OK even if that is granted, that still wouldn't make these rare drugs cheap.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by mjevans on Thursday May 25, 2017 @02:53AM (#14415733)
When money shouldn't be an object in the equation it should be removed from the equation.

This is work that should be done for public benefit by public benefit organizations.

In other words, universities should be where this kind of treatment is developed and tested, AND the regulations that make normal drugs so expensive should apply differently (and relate heavily to a LOT MORE public disclosure and real peer review).

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by replicatorblog on Thursday May 25, 2017 @08:51AM (#14416958)
That's a good hypothesis. How about someone suggests that Harvard, with its $36B endowment, tests it out? Pick a rare disease, ask Harvard, or any similar institution, to tackle it with their world class medical school and research capabilities. Offer them gov't matching funds. Or threaten their tax-exempt status if they don't do it. And let's see how they do.

Maybe a socialized or non-profit R&D program would do better than big biotech companies, but before we legislate this idea, how about we test it? My concern is that a non-profit/gov't drug development program will work as well as the ACA's $2B website.

I get hives whenever someone suggests pharma companies are "too" profitable. My daughter is alive today because these "greedy" pharma companies have developed chemotherapies that beat leukemia 90+% of the time. A 20% margin for these companies that regularly produce miracle drugs seems totally fair. Pharma is the closest thing we have to magic in the modern world.

I'm open to the idea there are better possible systems, but the burden of proof is on your side, not the side that regularly cranks out life-saving medicines like the goose that lays the golden eggs.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by malandrew on Thursday May 25, 2017 @02:59PM (#14419314)
I take an orphan drug myself to treat cataplexy/narcolepsy. I think the costs are around $60k to $80k per year and I'm of the exact same opinion as you. I have treatment today because we allow them to make a profit, and I'm only willing to try an alternative system when we prove through experimentation that this alternative system will actually produce as many treatments for orphan diseases at a cheaper price that makes the treatment available to more people.

Without the US healthcare system, my treatment simply would not exist. My treatment exists in no other country in the world.

Eventually, those that don't have insurance as good as mine will benefit from these drugs once the patent expires. It sucks that many people won't benefit until that happens, but under the alternative system SJWs are so keen to promote my treatment would never have been developed and I couldn't get this treatment at any price and no one in the future would get it either because their wouldn't be a treatment for a patent to expire on.

At the end of the day, the US is practicing "socialist" healthcare. It's socialist in the sense that it pays for a lot of the R&D that the rest of the world benefits from. 40% of the entire output of medical research globally comes from the US alone.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by brownbat on Thursday May 25, 2017 @08:06AM (#14416791)
> When money shouldn't be an object in the equation it should be removed from the equation.

We all believe it's important to save lives.

If it costs $300k to save one life, but in other disciplines or other areas of medicine you can save a life for $5k, then you have a problem that is not solved by simply ignoring money.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by rayiner on Thursday May 25, 2017 @10:25AM (#14417490)
> When money shouldn't be an object in the equation it should be removed from the equation.

Money is just a proxy for goods and services; in this case a proxy for having a bunch of highly skilled scientists and doctors work for years to treat a disease only a small group of people have. Having a public benefit corporation rather than a private company doesn't fundamentally change that dynamic.

As to regulations: at bottom, all they really require you to prove is safety and efficacy. If there was a cheap way to prove safety and efficacy, drug companies would just do that on the front end, and send only working drugs through the clinical process. But most drugs don't actually work; most actually fail clinical testing, many after they've made it pretty far along. If you get rid of that testing, and the safety and efficacy data that comes from it, what exactly do you disclose to the public?

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by TeMPOraL on Thursday May 25, 2017 @09:23AM (#14417095)
Money is the common unit we use to deal with resource scarcity. As long as there's more demand for care than care to go around, money will continue to be a part of the equation.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by arcbyte on Thursday May 25, 2017 @08:24AM (#14416841)
It doesnt matter where you move the money, its always in the equation.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by frgtpsswrdlame on Thursday May 25, 2017 @09:38AM (#14417177)
Gah those numbers don't work like that!! Alexion is a monopoly because of patent law, they are maximizing profit but they maximize profit in $ terms, not % margin terms. Alexion currently spends tons and tons of money on sales. Those sales expenditures only have to yield the slightest profit for them to partake because they don't give a rats ass about relative margins, only absolute profit. These lower profit activities bring the % margin down but overall profit up so the company engages in them. You can look at basically any drug and see that margin on it as a standalone is going to be incredible, they're super cheap to manufacture and you can charge as much as you want while it's under patent. If we limited the cost to $311,000 expenditures would be cut very slightly, the operating margin might move a bit but it would stabilize and they'd continue to make fantastic profits.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by johnnyhillbilly on Thursday May 25, 2017 @05:33AM (#14416214)
Sounds like they spend a lot of money on questionable "marketing". Also, one never knows where the true profits are recorded in the days of ubiquitous tax avoidance.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by epmaybe on Thursday May 25, 2017 @07:31AM (#14416650)
I'm not certain that marketing plays that huge of a role. They make the only drug on the market to treat hemolytic uremic syndrome, every medical student has to learn about it. Must be some other costs, or hiding of true profit as you suggest.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by eganist on Thursday May 25, 2017 @07:44AM (#14416698)
Sunk costs on failed treatments, generally. I don't remember the stat well enough, but it's something like a double-digit quantity of candidates fail for each single one that receives FDA approval.

Here's hoping someone else can investigate and share the exact number. I'm at a stoplight.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by tuna-piano on Wednesday May 24, 2017 @08:09PM (#14414419)
While the math isn't exactly right - even if Alexion returned all profits to its patients at the end of the year, the cost of the drug would still be only 20% less than the current price. So instead of $500k, it would be $400k. Would that really change the dynamics of the discussion?
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by refurb on Wednesday May 24, 2017 @09:38PM (#14414749)
Great point to call out. Also, Alexion uses about 21% of their revenue for R&D. So of the $500K they sell the product for, $100K is profit, $100K goes back into R&D and the rest is paying for expenses.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by dnautics on Wednesday May 24, 2017 @06:18PM (#14413911)
it's even crazier than that. Let's say that we institute some feel-good regulation that caps profits at 10% of cost. Presuming some sort of single payer system so that we don't have to feel guilty about screwing patients. What do I do as a pharmaceutical manufacturer? I'd overprovision FTEs on the production capability, encouraging them to spend "10%" time on other projects, ideation, but subtly encourage that 10% to be more. I'd create a QC system that is artificially stringent (make chromatography resins fail QC after single use) and recycle the QC-fail materials for pilot studies, etc...

There are always ways to sneakily increase costs. And I'm not going to lose sleep at night, since I am putting those funds back into "improving society".

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by vkou on Wednesday May 24, 2017 @07:02PM (#14414112)
I think the problem with pharma is not the profit margins, as much as the stupid amount of money that gets poured into marketing.

There is no indication that direct-to-consumer advertising of drugs improves health outcomes. It does, however, greatly increase the cost of medication. Since the marginal cost of producing more drugs is low, advertising, even at a positive RoI, leads to increased prices.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by refurb on Wednesday May 24, 2017 @09:29PM (#14414716)
There is no indication that direct-to-consumer advertising of drugs improves health outcomes.

Do you have an citations to back that up? Because I do. And it's from the FDA.[1] I'll spare copying it all down and just leave these takeaways:

- FDA research, of patients who visited their doctors because of an ad they saw, and who asked about that prescription drug by brand name, 87 percent actually had the condition the drug treats. And in 6 percent of those DTC-generated visits, a previously undiagnosed condition was discovered.

- Only 7 percent of doctors said they felt "very pressured to prescribe" a particular advertised drug.

- According to the FDA study, a majority of doctors feel that DTC advertising increases patient awareness and involvement, improves compliance, and enhances the overall doctor-patient relationship.

[1]https://www.fda.gov/drugs/resourcesforyou/consumers/ucm14356...

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by mjevans on Thursday May 25, 2017 @02:56AM (#14415743)
All that this tells me is that the current system for diagnosing patients is REALLY broken. Where's something like IBM Watson's doctor module to shortlist treatments for humans to undertake and evaluate?
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by epmaybe on Thursday May 25, 2017 @08:04AM (#14416773)
It seems weird then, that the American medical association lobbies against DTC advertising.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by upvotinglurker on Thursday May 25, 2017 @10:58AM (#14417709)
The subset of doctors who expend probably significant time/effort getting on the governing board (or whatever it may be called) of the AMA, maybe have different opinions than doctors in general? (I've found this sometimes to be true of professional organizations/unions)
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by epmaybe on Thursday May 25, 2017 @03:24PM (#14419469)
True, this is indeed possible. However, note that the FDA survey cited only asked 500 physicians. The survey was also done in 2004, which I believe is prior to the cracking down on gift giving and pharmaceutical companies giving kickbacks to physicians. If I remember correctly, DTC advertising spiked after this happened.

Here's some more recent data (also not super scientific, but probably a decent representation of most physician attitudes today): http://www.mmm-online.com/campaigns/what-doctors-have-to-say...

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by Brakenshire on Wednesday May 24, 2017 @07:36PM (#14414290)
Yes, I agree, I'm a big supporter of the pharmaceutical industry, it seems from random conversations that a significant proportion of people just think they are crooks, but clearly developing and testing drugs is expensive, that has to be paid for somehow, and private companies are completely indispensable to the process of drug development.

But, marketing is where my support starts to peter out. It seems crazy that marketing takes up such a large percentage of expenditure, it's not only wasteful but also introduces perverse incentives. I really think it would be great if trade deals could establish not just concessions like mandated strong intellectual property laws or restricted bulk negotiation, but also serious limitations on the other side of the coin, on something like pharma marketing.

If deep trade deals are justified by shaping the market to be at its most productive, I don't mind if that increases profits most of the time, but occasionally there will be measures that will improve the market but also reduce short term profit for some existing major players.

In practice, under the current situation the market is structured so that a profitable pharma company has to be good at generating demand, just as much as meeting a need. A company that can do the latter but not the former will go bust.

I think a world with more emphasis on judgements made by clinical research organizations (private or public) like NICE or the Cochrane Foundation rather than TV adverts, wine-ing and dining, and the nag factor on patients and overworked individual practitioners, would end up with a drastically more effective market for actually finding cures.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by refurb on Wednesday May 24, 2017 @09:30PM (#14414721)
It seems crazy that marketing takes up such a large percentage of expenditure, it's not only wasteful but also introduces perverse incentives.

How much do drug companies spend on marketing? I've only ever seen article mention SG&A which is an accounting catch all for more than just marketing.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by rayiner on Wednesday May 24, 2017 @10:14PM (#14414878)
I have my concerns about drug advertising, but pharma company SG&A isn't out of line with say tech company SG&A: For 2014-2015, the ratio between R&D spending and SG&A spending is 0.59 at Pfizer, 0.75 at Google, 0.56 at AstraZeneca, 0.43 at Apple, and 0.58 at Microsoft.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by Fomite on Thursday May 25, 2017 @12:08AM (#14415243)
Though in fairness, Apple isn't trying to get you to ask a licensed professional who has years of education about the new Apple Watch.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by spullara on Thursday May 25, 2017 @03:08AM (#14415791)
They might once it does glucose measurements... And I hope they do.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by barrkel on Thursday May 25, 2017 @05:40AM (#14416237)
How about prizes as a way of funding R&D? It's a different kind of profit motive, and it doesn't rely on monopolies and rent extraction to make things profitable. Once a drug is developed, it can be reproduced at close to cost.

https://en.wikipedia.org/wiki/Prizes_as_an_alternative_to_pa...

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by JamesBarney on Wednesday May 24, 2017 @07:56PM (#14414360)
The majority of advertising my pharmaceutical companies isn't direct to to consumer but to doctor's. And you're right it probably doesn't improve health outcomes, but I imagine most advertising doesn't improve consumer outcomes much.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by harryh on Wednesday May 24, 2017 @08:15PM (#14414453)
That is an interesting point but doesn't really have any thing to do with rare disease drugs. There is no marketing for these drugs.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by maxerickson on Wednesday May 24, 2017 @08:50PM (#14414601)
The sales rep calling up the doctor seems an awful lot like marketing.

Now a sales rep was on the other end of Owens’s phone from Alexion Pharmaceuticals Inc., the New Haven-based maker of Soliris—one of the world’s most expensive drugs, typically priced from $500,000 to $700,000 a year.

The rep was calling to argue with the treatment plan. She pressured Owens to continue Soliris treatments, ticking off detailed information about the mother’s organs that the doctor hadn’t shared with the drugmaker. “How did you know that?” Owens remembers thinking. She was monitoring the patient’s condition with seven hematologists and wasn’t swayed by the Alexion rep. “I was really taken aback by how bold and brash she was,” Owens says. “I’ve never had an experience like that—before or since.”

There was recently a discussion here about a new drug for ALS and when reading about it I took note of the line in the FAQ that mentions that anyone with a prescription can call the pharma company up and get a case manager to help explore their coverage and setup copay reimbursement ("Searchlight Support").

http://web.alsa.org/site/PageNavigator/alsa_radicava_faq.htm...

That's not exactly marketing, but it isn't really terrific that manufacturers are setting prices so high that they can spend significant resources helping people use their insurance.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by dmoy on Wednesday May 24, 2017 @08:56PM (#14414630)
Idk how to break out their financial statement, but in 2016 it looks like they spent a billion dollars on "sales, general, and administration" (distinct from cost of sales (250m) and R&D (750m).

I would imagine something in that billion dollars is marketing...

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by barrkel on Thursday May 25, 2017 @05:44AM (#14416250)
When the product is really important, we should change how we reward development, because if it's expensive, and we grant a monopoly, then the benefits of the product will be concentrated with the wealthy, rather than the many. And yes, that's not a good thing.

Consider prizes instead of patents: https://en.wikipedia.org/wiki/Prizes_as_an_alternative_to_pa...

We don't need to have a government enforced monopoly to support high prices to fund drug development. There are other ways that don't turn it into an economic ghetto either.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by kharms on Wednesday May 24, 2017 @06:30PM (#14413962)
> There is a tendency to believe that the normal dynamics of markets should be suspended when the product is "really important."

I've not seen the argument that they should be suspended as much as that they are. "Really important" just means that demand is inelastic.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by skybrian on Wednesday May 24, 2017 @10:11PM (#14414869)
Perhaps a temporary monopoly isn't the best way to reward these companies? Prize money might work better. Once the prize is awarded, there can be competition.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by ubernostrum on Wednesday May 24, 2017 @08:43PM (#14414574)
There is a tendency to believe that the normal dynamics of markets should be suspended when the product is "really important." Of course, that's backward. When the product is really important, the worst thing you can do is turn it into a low-profit economic ghetto by reducing incentives to invest.

You contradict yourself here.

The normal dynamics of markets have been suspended in order to ensure that "really important" products make it to market. That occurs through government-granted monopolies on drugs along with subsidies and grants on research. And that is what props up the market and provides the "incentive to invest" you insist is needed.

So you can argue for "normal dynamics" -- which would be a more free market with no government-granted monopolies, subsidies or research grants -- or you can argue to preserve "incentive to invest". But you can't have your cake and eat it, too, and the fact that you don't seem to consider how much we already do to meddle with the market in order to make sure "important" products are available is slightly worrying.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by finolex1 on Wednesday May 24, 2017 @08:40PM (#14414559)
It's highly debatable over whether lower profits will significantly reduce the incentive to invest, especially considering profits are already high (about 20%). A small drop won't make a significant difference for the lucrativeness of the industry. Perhaps the best way to go about doing this is by reducing patent lengths, rather than some other policy that is easy to circumvent/bend like taxes or price ceilings.

It's also worth noting that a large proportion of the basic research that goes into making these drugs is funded by the federal government or other research foundations, which receive little, if any of the benefits when commercialized. For instance, Alexion's drug is based to some extent on research conducted at Yale by its former CEO, not to mention the whole host of foundational research that preceded it.

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by refurb on Wednesday May 24, 2017 @09:33PM (#14414734)
A few thoughts since I worked for a biotech company.

R&D management sure as hell looks at the potential returns generated. I've been on projects where the company said "we're going to spend out $500M in R&D funds on this disease because we might actually make our money back. The other disease is off the table since we can't even break-even."

Yes, a lot of basic research is funded by the gov't, but that's minuscule compared to the funding the companies themselves put in. I sat in a meeting when a decision was made to move a promising compound forward. The investment? $400M for all activities post-phase 3. The NIH grants that supported the discovery? Maybe a few million?

Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by WalterBright on Thursday May 25, 2017 @01:52AM (#14415522)
If the risks of investing in X or Y are the same, but the rewards of X > Y, then investors will invest in X. Capping returns will result in investment dollars going elsewhere.
Re:When the Patient Is a Gold Mine: The Trouble with Rare-Di... by arjie on Thursday May 25, 2017 @06:58AM (#14416517)
Not going to argue about the drug issue but 20% profit margin is fantastic. That _is_ unusually lucrative.